Sammanfattning
We previously conducted a randomized double-blinded clinical cohort study on topical tacrolimus safety issues in 1-3-year-old children with atopic dermatitis. Five years on, the participants were contacted via a postal questionnaire to obtain long-term data. There were no significant differences regarding infections, growth parameters (height, weight, body mass index), quality of life and disease severity between use of topical tacrolimus and topical corticosteroids.
Originalspråk | engelska |
---|---|
Tidskrift | Clinical and Experimental Dermatology |
Antal sidor | 4 |
ISSN | 0307-6938 |
DOI | |
Status | Publicerad - 4 nov. 2023 |
MoE-publikationstyp | A1 Tidskriftsartikel-refererad |
Vetenskapsgrenar
- 3121 Allmänmedicin, inre medicin och annan klinisk medicin